SML4085
Pasireotide Acetate
≥95% (HPLC)
别名:
Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl] acetate, Cyclo[Phg-DTrp-Lys-Tyr(Bzl)-Phe-(2-aminoethy-carbamoyloxy-Pro)] acetate, SOM 230 acetate, SOM-230 acetate, SOM230 acetate
质量水平
方案
≥95% (HPLC)
表单
(Powder or Lyophilized powder or film)
储存条件
desiccated
颜色
white to off-white
储存温度
-10 to -25°C
相关类别
生化/生理作用
Somatostatin (SRIF) eptidomimetic with high affinity for somatostatin receptor subtypes STT1/2/3/5 and in vivo efficacy for suppressing GH secretion.
Pasireotide (SOM230) is a somatostatin (somatotropin release inhibiting factor, SRIF) eptidomimetic with high affinity for somatostatin receptor subtypes STT1/2/3/5 (IC50 = 9.3/1/1.5/0.16 nM), but not STT4 (IC50 > 1 μM). SOM230 potently inhibits the growth hormone (GH) releasing hormone (GHRH)-induced GH release in primary rat pituitary cultures (IC50 = 0:4 nM) and suppresses the secretion of GH, insulin and glucagon in rats in vivo (ED50 in μg/kg post 1h administration via s.c. = 0.22, 3.4, 74, respectively; GH ED50 post 6h = 5.5 μg/kg).
Pasireotide (SOM230) is a somatostatin (somatotropin release inhibiting factor, SRIF) eptidomimetic with high affinity for somatostatin receptor subtypes STT1/2/3/5 (IC50 = 9.3/1/1.5/0.16 nM), but not STT4 (IC50 > 1 μM). SOM230 potently inhibits the growth hormone (GH) releasing hormone (GHRH)-induced GH release in primary rat pituitary cultures (IC50 = 0:4 nM) and suppresses the secretion of GH, insulin and glucagon in rats in vivo (ED50 in μg/kg post 1h administration via s.c. = 0.22, 3.4, 74, respectively; GH ED50 post 6h = 5.5 μg/kg).
免责声明
Hygroscopic
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持